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A B S T R A C T
Introduction
This study aimed to evaluate the feasibility and benefit of a structured exercise intervention in people with Hunting-
ton's Disease (HD).
Methods
This study was conducted at 6 sites, and participants were randomized into either exercise or control (usual care)
groups, and were assessed at baseline, 13 and 26 weeks. The intervention was a 12 week, three times per week pro-
gressive exercise program, including aerobic (stationary cycling) and upper and lower body strengthening exercise
with tapered 1:1 support for 20 of 36 sessions.
Results
314 adults were assessed for eligibility: 248 did not meet inclusion criteria, 34 declined, and 32 were recruited and
randomized. Three individuals in the intervention group were withdrawn within the first month due to concomitant med-
ical conditions, resulting in 14 participants in intervention and 15 in control groups. There were two AEs in the inter-
vention group, both related to previous medical conditions, and there were two SAEs, both in the control group. The
intervention group had better fitness (predicted VO2 max difference: 493.3 ml min
−1, 95% CI: [97.1, 887.6]), lower UH-
DRS mMS (difference 2.9 points, 95% [−5.42, −0.32]) and lower weight at Week 13 (difference 2.25 kg, 95% CI: [−4.47,
−0.03]).
Conclusion
This study demonstrates that a short-term exercise intervention is safe and feasible. Individuals with HD may benefit
from structured exercise, and intensity, monitoring and support may be key factors in optimizing response. Larger scale
trials are now required to fully elucidate the extended clinical potential of exercise in HD.
Trial registration: Current Controlled Trials ISRCTN11392629.
© 2016 Published by Elsevier Ltd.
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1. Introduction
Aerobic and multi-modal exercise interventions are well known
for their effect on cardiorespiratory fitness, muscle strength, depres-
sion and cognition [1], and in recent years, benefits of exercise and
physical activity have been studied in Huntington disease (HD) ani-
mal models [2] and people with HD [3–6]. Furthermore, longer term
multidisciplinary rehabilitation has resulted in improvements in gait,
balance and quality of life [7,8], and evidence suggests it may impact
http://dx.doi.org/10.1016/j.parkreldis.2016.06.023
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cognitive function [9]. However, clear benefit as a result of participat-
ing in a shorter-term exercise program incorporating targeted aerobic
and strength training has yet to be established.
A variety of challenges are associated with exercise interventions
in people with complex neurodegenerative diseases such as HD, not
least that associated with cognitive and motor signs of the disease. In
a recent study, a home-based exercise intervention was well received
by participants; however, carer support was needed to facilitate and at
times supervise the exercise program [3]. Results from a gym-based
program suggest that while it was safe and feasible for individuals
to engage in an aerobic exercise program, overall intensity of the in-
tervention may not have been sufficient to achieve a training effect
[4]. Information obtained from process interviews also suggested that
some participants found the gym environment intimidating. In order to
develop a successful exercise intervention, acceptable to a wide num-
ber of people with HD, it is critical to include personal preferences of
exercise environment to facilitate uptake and adherence.
Complex physical and cognitive impairments in HD can impact
on a person's ability to initiate and adhere to an exercise program
[10]. Ensuring sufficient intensity of exercise to achieve an aerobic
effect is a further challenge. Thus a supported, structured, mixed de-
livery approach may facilitate a wider range of people with HD to
engage in exercise. Here we present results from a randomized con-
trolled trial of an exercise program delivered with tapered professional
support. This study was designed to evaluate a more intensive, pro-
gressive exercise program than has been previously studied in this
population. The specific objectives were to identify whether a
3-month, three times per week exercise program in people with HD
was: 1) safe, 2) feasible in terms of adherence and retention, 3) im-
proved physical fitness, and 4) improved functioning in other do-
mains, such as motor and cognitive function.
2. Methods
2.1. Study design
This was a single-blind, multi-site randomized controlled trial of
an exercise intervention compared to usual care. Assessments were
taken at baseline and 13 weeks. Follow up phone calls were made at
26 weeks to assess health status and physical activity. Fig. 1 illustrates
the CONSORT flowchart.
2.2. Site and participant selection
The trial was carried out at six HD specialist clinics that were EN-
ROLL-HD/Registry (13/WA/0192), sites: Cardiff, UK; Birmingham,
UK; Oxford, UK; Leiden, Netherlands; Münster, Germany; and Oslo,
Norway. ENROLL-HD is a worldwide observational study of Hunt-
ington's disease families, and provides a platform for clinical stud-
ies to facilitate recruitment into clinical trials. Exclusion and inclusion
criteria are shown in Table 1.
Fig. 1. ExeRT-HD CONSORT Flow chart.
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Table 1
Participant inclusion/exclusion criteria.
Inclusion criteria Exclusion criteria
1) genetically confirmed diagnosis of
HD
2) above the age of 18 years
3) stable medication regime for four
weeks prior to initiation of trial, and
anticipated to be able to maintain a
stable regime for the course of trial
1) any physical or psychiatric condition
that would prohibit the participant from
completing the intervention or the full
battery of assessments
2) inability to independently use the
exercise bike
3) unable to understand or communicate
in spoken English (UK sites only)
4) currently involved in any intervention
trial or within four weeks of completing
an intervention trial
5) current, regular participation in a
structured exercise program five times
per week or more
HD = Huntington's disease.
2.3. Recruitment
The recruitment period was March 2014 to January 2015 with a
target of 42 participants. Patients receiving routine HD clinical care or
attending an ENROLL-HD assessment were given trial information.
An invitation letter and information sheet was sent to ENROLL-HD
patients who were potentially eligible but not due to visit clinic im-
minently; those participants subsequently attended an ENROLL-HD
appointment and were reviewed by the site Principal Investigator (PI).
All participants gave written informed consent. Site PIs were respon-
sible for ensuring that each participant was capable of giving informed
consent.
2.4. Screening
Each site kept a screening log, which recorded details of number of
people approached about the trial and eligibility.
2.5. Blinding
Data collection was conducted by blinded assessors. Site coordi-
nators requested participants not disclose their allocation to the asses-
sors. Incidents of unblinding were recorded.
2.6. Randomization
The trial coordinator performed randomization centrally for each
participant during their baseline assessment; group assignment was
conveyed to respective site coordinators by phone, who then informed
the participant privately following completion of baseline assessment.
Randomization ratio of intervention to control arm was 1:1. A mini-
mization procedure [11] was used to achieve balance between groups;
variables used for minimization were site, age, gender, and Unified
Huntington's Disease Rating Scale Total Motor Score (UHDRS TMS)
[12].
2.7. Intervention
The intervention group participated in a 12-week exercise pro-
gram; control group was asked to continue as usual. The intervention
consisted of a 50-min structured aerobic, strengthening and stretching
routine, and could take place either in a hospital-based gym, or partic
ipant's home with exercise equipment provided by the researchers.
Physical therapists or certified fitness professionals (referred to as
trainers henceforth) delivered the intervention, and monitored pre-
scribed exercise dose, progression and safety. Trainers provided sup-
port in a tapered process for 20/36 sessions: for weeks 1–2, trainers
supervised 3/3 sessions; for weeks 3–6, 2/3 sessions were supervised
with 1 independent session; for weeks 7–12, 1/3 sessions were super-
vised.
Sessions followed a set program including a 5-min warm up and
up to 25 min on the bike within an aerobic zone. Intensity of warm-up
was at 50–60% age predicted maximum heart rate (APMHR, defined
as 220-age) and aerobic zone was in a range of 65–85% APMHR.
Trainers progressed participants by initially working to achieve the
full 30 min of training time and then increasing intensity within the
training zone. During the last 3 min, intensity was tapered to the lower
end of training zone. Following the aerobic exercise was 10–15 min of
strengthening, consisting of lower extremity and core activities, end-
ing with 5 min of stretching (see Appendix 1).
In supported sessions, trainer's recorded detailed resistance, speed
of pedalling, heart rate (HR) and perceived exertion at 5-min intervals
for aerobic training on the bike, and sets, repetitions and weights for
strengthening exercises. Participants were provided with exercise di-
aries for independent sessions.
Participants assigned to the control group were instructed to con-
tinue as normal. Following completion of the study, control group par-
ticipants were offered gym membership for 12 weeks or a home exer-
cise bike, including two trainer visits.
2.8. Safety for exercise
Participants were screened for risk factors for exercise [13], and
completed the Physical Activity Readiness Questionnaire (PAR-Q)
[14] and a resting electrocardiogram (ECG) to ensure safety to initiate
an exercise program. If abnormal results were found participants were
referred to their primary physician or cardiologist, depending on the
site, for further evaluation before being allowed to enrol in the trial.
2.9. Baseline assessment
We collected demographic data of age and gender, and height and
weight were measured. Medication was recorded at baseline and any
medication changes at Week 13 were noted. Medications were coded
according to classification and indication.
2.10. Outcomes
Outcomes of safety, feasibility, and effectiveness were assessed.
Safety was assessed by review of weekly health and falls diaries,
which included information on falls history, medication changes,
healthcare service use and hospital admissions (classified as adverse
events (AEs)). Diaries were given to all participants at baseline assess-
ment and were returned at Week 13.
The primary feasibility objective was evaluation of recruitment, re-
tention and adherence rates. Recruitment was assessed using site re-
cruitment logs. Retention rate was measured as percentage of individ-
uals who completed the intervention. Adherence rates were defined
as percentage of intervention sessions completed. Successful inter-
vention adherence was pre-defined as at least 75% of supervised ses-
sions (15/20 sessions), and 75% of unsupervised sessions (12/16 ses
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sions), completed with average HR over session duration within the
aerobic zone.2
The primary efficacy outcome in terms of short-term benefit was
physical fitness measured using a predicted VO2 max equation [15],
by stepwise incremental exercise test (Appendix 2).3 Expired air and
capillary blood samples4 were collected at two sites during the ex-
ercise test. Expired air measures provided information about gas ex-
change during exercise, which was used to validate the predicted test
equation [15].
Secondary outcome measures included measures of motor func-
tion, ambulation and cognition (Appendix 3).
2.11. Training and site monitoring
We conducted a one-day training for assessors and trainers, which
was videotaped for future viewing. Additional on-site training was
conducted.5 Assessors conducting UHDRS TMS and mMS were re-
quired to have Motor Rating Certification [16]. Monitoring occurred
face-to-face or via remote video on at least two occasions per site.
Trainers maintained detailed session notes for each training session,
which were reviewed by the PI during the trial to assure intervention
fidelity.
2.12. Sample size
We planned to recruit 42 participants to allow us to estimate any
feasibility proportion to within plus or minus 15.1% points. While
demonstrating efficacy was not an aim of the study, with 34 partici-
pants in total (17 per group, 20% attrition) we could detect a standard-
ised difference of 1.0 at the final measurement point with a power of
80%.
2.13. Statistical analysis
Descriptive data includes evaluation of eligibility, recruitment, re-
tention and adherence rates with 95% confidence intervals. Predicted
VO2 max was compared to actual VO2 max (baseline) on data from
two sites using Pearson correlation coefficients. Graphical illustrations
were used to check distributions of outcome data. Primary and sec-
ondary analyses compared outcome measures between intervention
and control groups, using Analysis of Covariance (ANCOVA) con-
trolling for age, UHDRS TMS, gender and baseline measure on the
outcome of interest. A pre-defined statistical analysis plan was fol-
lowed. All analyses were conducted on an intention-to-treat basis; pri-
mary analysis used complete case data set.
2.14. Ethics
The trial was approved by Wales Research Ethics Committee 2
(Wales REC 2; 13/WA/0315).
2 Acceptability of the intervention and further analysis of intervention fidelity and
progression was assessed via structured questionnaires with research participants
and trainers on completion of the intervention will be reported elsewhere;
manuscript in preparation.
3 Cardiff and Oxford sites utilized Lode Excalibur Sport bike, Gronigen,
Netherlands; all other sites utilized a Monarch 874E bike, Monark Exercise AB,
Vansbro, Sweden).
4 Full results from the expired air and blood samples will be reported elsewhere;
manuscript in preparation.
5 Training for the Norway site, which was added mid-way through the trial, was
conducted via remote video-conferencing.
3. Results
3.1. Recruitment and randomization
Three hundred and fourteen adults were assessed for eligibility
over 11 months, and 32 were recruited and randomized (50%, 95%
CI [38.1,61.9]) (see Fig. 1). Recruitment was monitored throughout
the trial; two sites had low recruitment secondary to staffing issues,
so another site was added. Seventeen participants were randomized to
intervention; eight exercised at home and nine in a hospital/research
laboratory. Twenty-six of the 32 participants were taking one or more
medications at the time of baseline assessment. Table 2 provides base-
line data and medication use for both groups.
3.2. Adverse events (AE)
Two AEs occurred in the intervention group. Symptoms of con-
comitant conditions were aggravated during the intervention (recur-
rence of back pain in one participant and Wolf Parkinson White syn-
drome in another). The participants were subsequently withdrawn.
Two serious adverse events (SAEs) occurred in the control group. One
SAE was attempted suicide, which occurred within one week after
Week 13 Assessment, and was classified as possibly related. While it
is impossible to make a direct correlation between the assessment and
attempted suicide, the worst-case classification was adopted. The par-
ticipant was hospitalized and returned home with community psychi-
atric team support. The other SAE was a suicide and classified as un-
likely to be related.6
3.3. Retention
Three individuals (intervention group) were withdrawn within the
first month due to concomitant medical conditions (Fig. 1), resulting
in 14 participants in the intervention and 15 in the control group for
final analysis (retention rate of 90.6%, 95% CI [73.4, 97.5]. All asses-
sors remained blinded throughout the study.
3.4. Intervention adherence
Thirteen of the 14 participants who completed the trial completed
>75% of the required sessions (92.9%, 95% CI [64.2,99.6]); one par-
ticipant completed 61% of sessions secondary to illness. For the aer-
obic exercise, 10/13 achieved average target HR within aerobic zone
(65–85% APMHR) for at least 75% of the sessions; 3/13 were able to
achieve HR at 60% APMHR. UHDRS TFC scores for these partici-
pants were 2, 6, and 7 and UHDRS TMS were 85, 65 and 66 respec-
tively, indicative of middle-late stages of the disease.
3.5. Falls
Twenty-one out of 32 participants completed the health and falls
diaries. Mean (median) number of falls in control group was 1.12(1)
(n = 8; 1 excluded) and 0.83(0) (n = 12) in intervention group. Diaries
for one participant were excluded due to inaccurate completion.
6 The site PI confirmed that there were no suicidal plans at the time of the
participant's most recent clinical visit. The SAE occurred 3 months following the
second assessment and 2 months following the last study contact date when the
trainer delivered the control intervention program between Assessment 2 and 3.
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Table 2
Baseline Characteristics and Medication use for all participants. Mean (SD)
[Range] Scores are reported for age, Total functional capacity, Total Motor score,
and Symbol Digit Modality.
Variable Control group (n = 15)
Intervention group
(n = 17)
Gender (men:women) 7:8 9:8
Age (y) 51(17) [19–76] 53 (11) [22–69]
Total functional
capacity score (TFC)
9 (3) [3–13] 8 (3) [2–13]
UHDRS Total Motor
Score (TMS)
32 (14) [12–54] 39 (22) [4–85]
UHDRS Symbol Digit
Modality Test
Cognitive assessment
(SDMT)
28 (10) [14–45] 23 (9) [6–44]
Medications Antichoreic (n = 4)
Antidepressant (n = 8)
Antihypertensive (n = 1)
Analgesic (n = 4)
Other (n = 8)
Antichoreic (n = 4)
Antidepressant (n = 11)
Antihypertensive (n = 4)
Analgesic (n = 0)
Other (n = 8)
Medication changes n = 3
Addition of anti-choreic
(n = 1); Addition of diabetes
management medication
(n = 1); Curse of antibiotics
(n = 1)
n = 2
Increase in anti-
hypertensive (n = 1);
Decrease in anti-
depressant (n = 1)
3.6. Outcomes
Predicted VO2 max for each participant at two sites was compared
to actual VO2 max obtained from expired air (r = 0.88, n = 15
7).
The intervention group had better fitness as measured by pre-
dicted VO2 max (Table 3) (difference: 493.3 ml min
−1, 95% CI:
[97.1,887.6]). There was also improvement on UHDRS mMS (inter-
vention arm 2.9 points lower, 95% [−5.42, −0.32]). Weight was dif-
ferent between groups at follow up (intervention arm 2.25 kg lighter
95% CI: [−4.47, −0.03]). There were no differences between groups
on other outcome measures.
At Week 26 phone call, nine control participants and nine interven-
tion participants provided EQ-5D scores. EQ-5D mean (SD) scores in
control and intervention arms were 0.78(0.14) and 0.80(0.21) respec-
tively. Eight control participants and nine intervention participants
provided IPAQ scores. Mean (SD) IPAQ scores in control and inter-
vention arms were 1753(1802) and 988(890) respectively.
4. Discussion
Here we report data from a short-term, multi-modal exercise pro-
gram in people with HD with tapered support. The intervention was
safe and feasible, and evaluation of exploratory outcomes revealed
significant improvements in fitness and motor function. We demon-
strated that people with HD could exercise safely in an aerobic zone
and conduct progressive strengthening exercises, despite the presence
of sometimes advanced motor impairments. Importantly, individuals
in the intervention group did not have a greater incidence of falls or
AEs compared to control participants.
7 Data from 2 participants at the Cardiff site is missing from this analysis; one due
to difficulty with a participant using the equipment, one secondary to equipment
malfunction.
Individuals in the intervention group demonstrated lower weight at
Week 13 compared to control group. While in the general population
weight loss after exercise is generally considered a positive outcome,
in this population it is not necessarily desirable. Weight loss is com-
mon in HD and has been shown to be correlated with CAG repeat [17].
Previous studies in animal models of HD have also shown a propen-
sity towards weight loss following exercise [2]. The role of nutrition to
supplement potential weight loss from increased physical activity will
be an important component of future trials and should likely include
analysis of body composition.
This study initially aimed to recruit 42 participants, which was not
achieved within a 10 month time period; this was primarily due to site
staffing issues. In addition, we had a large number of participants who
did not meet inclusion/exclusion criteria. While many of these individ-
uals had psychiatric or behavioural problems, these criteria conceiv-
ably excluded potential participants who may benefit most from exer-
cise, such as those with anxiety or depression. Despite this, our study
included individuals with a wide range of motor and functional capac-
ity.
Physical limitations and inability to use the exercise bike were also
primary reasons for exclusion; this was likely representative of indi-
viduals in the mid-late stages of the disease, who may be more appro-
priate for other types of rehabilitation intervention (e.g. task specific
training [18]). In addition approximately 20% of participants lived too
far away to participate, either for the participant or trainer to travel
for training sessions. As HD is a relatively rare disease, future studies
should include strategies to promote remote training and monitoring,
or local professionals to support exercise programs.
This intervention incorporated a tapered support program, provid-
ing 1:1 instruction for the first weeks that decreased over 12 weeks.
Trainers served two important purposes: to monitor that the program
was being conducted as intended, and to provide support and encour-
agement to facilitate adherence. The support structure appears to have
been effective, in that 13/14 participants adhered to the program, with
only one participant having lower than 75% adherence secondary to
illness. Follow up phone calls at Week 26 suggested that while gen-
eral health outcome remained relatively unchanged, participants in the
intervention group appeared to return to low levels of physical activity
after the support structure was removed.
Three participants in this study were unable to consistently achieve
65% APMHR while exercising on the bike. This was likely due to mo-
tor and coordination impairments, which may make it difficult for peo-
ple with HD to maintain the speed necessary to achieve a higher HR.
Despite this, an overall effect of improving fitness was seen, which
indicates that in this population 60% APMHR may be adequate to
achieve a training effect (e.g. change in VO2 max).
Positive results in terms of safety, feasibility and outcomes suggest
that a larger scale, confirmatory trial of exercise intervention in peo-
ple with HD is now warranted. This study has indicated that predicted
VO2 max is sensitive to change in this population, and thus demon-
strates the construct validity of VO2 max as an outcome measure for
an exercise intervention in this population. For future studies, based
on the observed effect size in predicted VO2 max of 0.73 we would
require 41 participants per group (for analysis) in order to have 90%
power to identify this effect as statistically significant at the 5% level
using a two –sided comparison of means.
4.1. Limitations and future directions
As a feasibility study, and one of the first to systematically eval-
uate a multi-modal exercise intervention in HD, we considered it im-
portant to not add complexity through the introduction of an active
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Table 3
Unadjusted Descriptive Statistics Split by Group for all Outcome Measures at baseline and 13 weeks, along with adjusted treatment effect estimates from a complete case ANCOVA
Analysis.
Construct Outcome measure Baseline Week 13
Adjusted estimate of visit 2 and effect
sizes from ANCOVAa
p-
value
Control Intervention Control Intervention
Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) n
Treatment effect estimate
(95% CI)
Effect
size
Fitness Predicted VO2 Max
(ml.min-1)
1767.39
(755.28)
15 1585
(546.14)
17 1812.49
(672.5)
13 2045.77
(687.66)
14 492.32 (97.08, 887.56) 0.73 0.02
Motor
function
UHDRS modified Motor
Score (mMS) [21]
15 (7) 15 18 (7) 17 14 (7) 15 16 (7) 14 −2.87 (−5.42, −0.32) −0.43 0.03
15 rep chair stand time (sec)a
[22]
47.1 (19.9) 15 47 (26.6) 17 42.3 (17.3) 15 47.6 (21.4) 14 −5.57 (−23.99, 17.32) N/A 0.59
Three minute walk (m) [23] 213.7 (72.6) 15 225.8 (73.8) 17 220.1 (71.1) 15 218.5 (50.9) 14 4.68 (−20.38, 29.74) 0.08 0.70
Finger Tapping score (no.taps
in 10 s)a [24]
33.6 (12.4) 15 27.5 (13.1) 16 34.4 (13.4) 15 30 (11.3) 14 12.69 (−9.22, 39.88) N/A 0.26
Physical
Activity
IPAQ MET-Minutes [25] 1335.2
(1002.7)
15 1249.7
(1054.4)
17 1347.7
(1839.7)
15 3104.4
(3836.7)
14 1288.67 (−459.05, 3036.4) 0.42 0.14
Dual-tasking Simple dual task walk time
(sec) [26]
14.04 (7.02) 15 12.85 (4.11) 17 13.08 (6.38) 15 12.54 (3.61) 14 0.29 (−2.79, 3.37) 0.06 0.85
Complex dual task walk time
(sec) [26]
22.93 (19.5) 15 16.41 (4.99) 17 17.84
(10.06)
15 15.48 (5.03) 14 1.42 (−2.71, 5.56) 0.18 0.48
Cognition Symbol Digit Modalities Test
(no. correct) [27]
28 (10) 15 23 (9) 17 29 (9) 15 23 (12) 14 0.09 (−3.04, 3.22) 0.01 0.95
Category Verbal Fluency (no.
correct) [12]
17 (5) 15 13 (6) 17 17 (5) 15 12 (5) 14 −1.13 (−4.83, 2.57) −0.2 0.53
Stroop colour naming (no.
correct) [12]
47 (12) 15 41 (16) 17 48 (13) 15 39 (14) 14 −4.27 (−10.16, 1.63) −0.31 0.15
Word reading (no correct)
[12]
64 (15) 15 57 (21) 17 65 (22) 15 53 (19) 14 −5.39 (−17.55, 6.76) −0.26 0.36
Interference (no correct) [12] 27 (8) 15 23 (9) 17 27 (9) 15 23 (9) 14 0.71 (−3.79, 5.21) 0.08 0.74
Trailmaking A time (sec)a
[27]
54.9 (22.3) 15 82.1 (59.2) 17 51.7 (18.7) 15 91.6 (61.7) 14 8.54 (−12.39, 34.45) N/A 0.43
Trailmaking B time (sec) [27] 133 (69) 15 153.1 (65.7) 15 145.2 (71.9) 15 171.5 (79.4) 14 −1.76 (−40.86, 37.33) −0.02 0.92
Depression Hospital Anxiety and
Depression Scalea [28]
11 (9) 15 9 (9) 17 11 (9) 15 7 (6) 14 −20.61 (−59.55, 54.9) N/A 0.50
Global Health EQ-5D-3L [29] 0.74 (0.17) 15 0.77 (0.19) 17 0.75 (0.19) 15 0.81 (14) 14 0.055 (−0.097, 0.207) 0.34 0.42
Weight Weight (kg) 76.5 (18.3) 15 79.9 (16.5) 17 77.2 (18.3) 15 80 (16.3) 14 −2.25 (−4.47, −0.03) −0.13 0.05
a Log transformed hence % difference between arms (with 95% CI) or Odds ratios (with 96% CI) for dichotomised variables rather than adjusted treatment effect (indicated with
grey shading).
comparator, which should be included in future studies. These may in-
clude interventions that focus on physical activity education as well
as different modes and intensities of exercise. Future studies should
also consider additional measures of functional abilities, disease-spe-
cific quality of life and measures of muscle strength.
While this study demonstrated changes in fitness and motor func-
tion, there was not carry over to walking ability or sit to stand, or to
cognitive function. Extending the intervention to longer durations may
be important to evaluate the potential for exercise to have effects on
cognition and other functional abilities [19,20]. Furthermore, exercise
may be most feasible and have the potential for disease modification
for individuals in the pre-manifest or prodromal stages of HD, and
consideration of early intervention is necessary. Finally, studies are
needed to fully understand the mechanistic underpinnings by which
exercise can exert its effects across all stages of the disease.
The findings in this study are generalizable to a relatively limited
number of individuals with HD, who are mobile and have limited be-
havioural or psychiatric issues. We recognize that our exclusion cri-
teria potentially limited a large number of individuals with HD who
may have most benefited from the intervention, however we believed
it important to set these criteria as a minimum requirement for ethical
and scientific reasons and to establish feasibility in a subgroup most
likely to complete and potentially benefit from the intervention.
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